Clinical Trial Update: Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nivolumab with or without ipilimumab in patients with resectable hepatocellular carcinoma has completed; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Resectable Hepatocellular Carcinoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Hepatocellular Carcinoma, Resectable Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2023-07-10